User menu

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.

Bibliographic reference Devogelaer, Jean-Pierre ; Brown, J P ; Burckhardt, P. ; Meunier, P J ; Goemaere, S. ; et. al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.. In: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, Vol. 18, no. 9, p. 1211-8 (2007)
Permanent URL http://hdl.handle.net/2078.1/10974
  1. Mellström DD, Sörensen OH, Goemaere S et al (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462–468
  2. Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 350:1189–1199
  3. Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661
  4. Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526–1536
  5. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282(14):1344–1352, Oct 13
  6. Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. Fracture Intervention Trial Study Group. J Bone Miner Res 19:1250–1258
  7. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
  8. Recker R, Stakkestad JA, Chesnut CH et al (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899
  9. Reginster JY, Christiansen C, Roux C et al (2001) Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporosis Int 12:169–177